Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Financial Performance - Glaukos reported revenue of $96 67 million for the quarter ended September 2024, a year-over-year increase of 23 9$0 28, an improvement from -$0 50 in the same period last year [1] - The revenue surpassed the Zacks Consensus Estimate of$91 32 million by 5 86% [1] - EPS also exceeded the consensus estimate of -$0 52, with a surprise of +46 15$51 57 million, a 35 5% increase year-over-year and above the five-analyst estimate of $47 06 million [3] - Revenues from Corneal Health in the United States were$18 45 million, a 6 4% increase year-over-year and slightly above the five-analyst estimate of $17 98 million [3] - International revenues totaled$26 65 million, a 17 7% increase year-over-year and above the five-analyst estimate of $25 93 million [3] - Revenues from Corneal Health internationally were$2 19 million, a 7 8% decrease year-over-year and below the five-analyst estimate of $2 50 million [3] - Total United States revenues were$70 02 million, a 26 4% increase year-over-year and above the five-analyst estimate of $65 04 million [3] - Revenues from Glaucoma internationally were$24 47 million, a 20 7% increase year-over-year and above the five-analyst estimate of $23 42 million [3] - Total Corneal Health revenues were$20 64 million, a 4 7% increase year-over-year and slightly above the six-analyst estimate of $20 40 million [3] - Total Glaucoma revenues were$76 03 million, a 30 3% increase year-over-year and above the six-analyst estimate of $71 18 million [3] Stock Performance - Glaukos shares returned +3 9% over the past month, outperforming the Zacks S&P 500 composite's -0 5% change [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]